Patents by Inventor Yhun Yhong Sheen

Yhun Yhong Sheen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating fibrosis, cancer and vascular injuries
    Patent number: 8513222
    Abstract: This invention relates to use of inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: August 20, 2013
    Assignee: EWHA University—Industry Collaboration Foundation
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Domalapally Sreenu, Kota Sudhakar Rao, Maddeboina Krishnaiah, Vura Bala Subrahmanyam
  • 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS
    Publication number: 20110319406
    Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.
    Type: Application
    Filed: June 29, 2010
    Publication date: December 29, 2011
    Applicant: EWHA University-Industry Collaboration Foundation
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Domalapally Sreenu, Kota Sudhakar Rao, Maddeboina Krishnaiah, Vura Bala Subrahmanyam
  • Methods of Treating Fibrosis, Cancer and Vascular Injuries
    Publication number: 20110319408
    Abstract: This invention relates to use of inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.
    Type: Application
    Filed: June 24, 2011
    Publication date: December 29, 2011
    Applicant: EWHA University-Industry Collaboration Foundation
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Domalapally Sreenu, Kota Sudhakar Rao, Maddeboina Krishnaiah, Vura Bala Subrahmanyam
  • 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
    Patent number: 8080568
    Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: December 20, 2011
    Assignee: EWHA University - Industry Collaboration Foundation
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala
  • Stable injection formulation containing paclitaxel
    Patent number: 6046230
    Abstract: This invention relates to a stable injection paclitaxel formulation having polyoxyethylene sorbitol oleic polyester as a main solubilizer, and appears to have less toxicity and greater stability compared to polyethoxylated castor oil-containing formulation which is clinically used all over the world. The formulation includes paclitaxel 30 mg, povidone 80 mg, oxyethylene sorbitol oleate 0.5 to 2.0 ml, (oxyethylene glycol).sub.15-20 fatty acid monoester 0.5 to 2.0 ml, polyethylene glycol 1.0 ml, and anhydrous alcohol 2.0 ml. The oxyethylene sorbitol oleate is either (oxyethylene).sub.60 sorbitol tetraoleate or (oxyehtylene).sub.45 sorbitol trioleate.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: April 4, 2000
    Assignee: Kyu-Nung Chung
    Inventors: Kyu-Nung Chung, Yhun-Yhong Sheen, Hyun-Jong Shin
  • 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
    Patent number: RE47122
    Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 13, 2018
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala
  • Methods of treating fibrosis, cancer and vascular injuries
    Patent number: RE47141
    Abstract: This invention relates to use of inhibitors of the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 27, 2018
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Dae-Kee Kim, Yhun Yhong Sheen, Chenghua Jin, Chul-Yong Park, Sreenu Domalapally, Sudhakar Rao Kota, Krishnaiah Maddeboina, Subrahmanyam Vura Bala